drugset
drugset / Trial / NCT05248672

Study to Assess the Pharmacokinetics of CT1812 in Older Healthy Volunteers

NCT05248672 ↗

Phase 1 Completed 35 enrolled Cognition Therapeutics
RandomizedParallel-groupQuadruple-blindBasic science

Summary

This an open label study to assess the pharmacokinetics of CT1812 in normal healthy volunteers.

Timeline

Start
2022-02-15
Primary completion
2022-06-01
Completion
2022-06-01

Drugs

EvaluationDrugModalityDoseRoute
Subject CT1812 Small molecule 150 mg —
Subject CT1812 Small molecule 300 mg —

Indications

Alzheimer disease